- PR Newswire•17 days ago
NASHVILLE, Tenn., Feb. 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) today announced the publication of a multicenter clinical study demonstrating that Caldolor® (ibuprofen) Injection delivered significant fever reduction in hospitalized children. This study, which adds to the growing body of literature supporting Caldolor, evaluated the efficacy and safety of intravenous ibuprofen in pediatric patients, six months and older, with fever. This pivotal data supported the FDA approval of Caldolor for use in this pediatric patient population.
- PR Newswire•25 days ago
NASHVILLE, Tenn., Jan. 30, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced that on January 26, 2017, the U.S. Court of Appeals for the Federal Circuit ruled in favor of Cumberland in a patent case associated with its Acetadote® product. Cumberland developed, registered, and launched Acetadote, which is now a standard of care for the leading cause of poisoning in the U.S. The patent that was challenged has claims associated with Cumberland's next-generation formulation of Acetadote that is free of EDTA or any other preservative, chelating, or stabilizing agent.
- PR Newswire•last month
NASHVILLE, Tenn., Jan. 16, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) is pleased to announce the addition of Kenneth J. Krogulski, CFA to its Board of Directors. Mr. Krogulski has over 37 years' experience in security analysis and portfolio management.
CPIX : Summary for Cumberland Pharmaceuticals Inc. - Yahoo Finance
Cumberland Pharmaceuticals Inc. (CPIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Ask||12.00 x 1200|
|Day's Range||5.53 - 5.77|
|52 Week Range||4.20 - 6.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1,903.33|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|